文献速递物质与行为成瘾

代谢型谷氨酸受体变构调节剂对药物自我给药与复吸的影响:临床前研究综述及临床意义

Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications.
PubMed 文献 · Biol Psychiatry · 2017-09-05

该综述汇总近20年啮齿类动物研究,提示谷氨酸传递参与药物自我给药与复吸模型,离子型或代谢型谷氨酸受体拮抗剂及mGluR2/3正构激动剂可减少动物自我给药与复吸,但因潜在副作用等未进入临床。近期研究关注mGluR的正/负变构调节剂(PAMs/NAMs),系统注射或颅内注射在啮齿类和猴中可减少药物自我给药、复吸唤起及渴求孵化,作者认为应考虑开展临床试验。

要点

  • 谷氨酸传递参与药物自我给药与复吸的动物模型。
  • mGluR的PAMs和NAMs可抑制诱发性谷氨酸释放并在动物中减少药物自我给药与复吸。
  • 作者建议将mGluR的PAMs和NAMs推进临床试验。

核心结论

  • 代谢型谷氨酸受体的正变构调节剂和负变构调节剂应被考虑用于临床试验。

研究设计与样本

  • 综述近20年临床前啮齿类动物研究及近期啮齿类和猴研究,涵盖系统注射与颅内注射mGluR的PAMs和NAMs。

主要发现

  • 系统注射离子型谷氨酸受体或mGluR拮抗剂或mGluR2/3正构激动剂可减少啮齿类和灵长类模型的药物自我给药与复吸。
  • 系统注射mGluR的PAMs或NAMs在啮齿类和猴中可减少药物自我给药、药物寻求的复吸唤起及药物渴求的孵化。
  • 颅内注射mGluR的PAMs或NAMs在大鼠中可减少药物自我给药与复吸。
  • 上述拮抗剂或正构激动剂因潜在副作用及其他因素未推进至临床使用。

临床怎么用

  • 基于临床前证据,mGluR的PAMs和NAMs可考虑作为成瘾治疗的临床试验候选药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Results from preclinical rodent studies during the last 20 years implicated glutamate neurotransmission in different brain regions in drug self-administration and rodent models of relapse. These results, along with evidence for drug-induced neuroadaptations in glutamatergic neurons and receptors, suggested that addiction might be treatable by medications that inhibit glutamatergic responses to drugs of abuse, drug-associated cues, and stressors. This idea is supported by findings in rodent and primate models that drug self-administration and relapse are reduced by systemic injections of antagonists of ionotropic glutamate receptors or metabotropic glutamate receptors (mGluRs) or orthosteric agonists of mGluR2/3. However, these compounds have not advanced to clinical use because of potential side effects and other factors. This state of affairs has led to the development of positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) of mGluRs. PAMs and NAMs of mGluRs, either of which can inhibit evoked glutamate release, may be suitable for testing in humans. We reviewed results from recent studies of systemically injected PAMs and NAMs of mGluRs in rodents and monkeys, focusing on whether they reduce drug self-administration, reinstatement of drug seeking, and incubation of drug craving. We also review results from rat studies in which PAMs or NAMs of mGluRs were injected intracranially to reduce drug self-administration and reinstatement. We conclude that PAMs and NAMs of mGluRs should be considered for clinical trials.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Caprioli D, Justinova Z, Venniro M, et al. Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications. Biol Psychiatry. 2017. PMID: 29102027. doi:10.1016/j.biopsych.2017.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。